$25.33
-0.60-2.31%
Last update: Oct 27, 2:23 AM
Rapport Therapeutics Inc (RAPP) Stock Price, Quote, News & History
RAPPNASDAQ
Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner, with FDA filing planned for 2026.
You can purchase shares of Rapport Therapeutics (NASDAQ:RAPP) through any online brokerage.
Other companies in Rapport Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Rapport Therapeutics has a consensus price target of $57.71.
The stock price for Rapport Therapeutics (NASDAQ: RAPP) is $25.16 last updated October 27, 2026 at 2:23 AM EDT.
There are no upcoming dividends for Rapport Therapeutics.
Rapport Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Rapport Therapeutics.
Rapport Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its...
